Life Science & Biotech

Indiana's growth in life sciences jobs beats national average

May 8, 2010
 IBJ Staff
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
More

Dow AgroSciences' profit rises despite lower revenue

April 28, 2010
 IBJ Staff and Associated Press
The Indianapolis unit of Dow Chemical sees quarterly profit rise 6 percent, to $384 million, despite an 8-percent dip in revenue. The parent company reports strongest quarterly results in more than a year.
More

Chao exit hurts drug development industry

April 28, 2010
J.K. Wall
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
More

Judge rejects Guidant's defibrillator plea deal

April 27, 2010
Bloomberg News
A federal judge has rejected Guidant Corp.'s guilty plea to charges it hid defects in heart defibrillators, after some doctors and patients complained about the $296 million deal.
More

Medical device startup FlowCo enlists Guidant alums

April 24, 2010
Chris O'Malley
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement product to market as soon as 2011.
More

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More

Ariad loses $65M patent appeal against Eli Lilly

March 22, 2010
Bloomberg News
Monday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis drug Evista and sepsis medicine Xigris.
More

FDA says 'not yet' on Lilly's once-weekly Byetta

March 15, 2010
J.K. Wall
Regulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling, manufacturing processes.
More

Eli Lilly to buy European rights to Pfizer animal products

March 8, 2010
Scott Olson
The acquisition will benefit Elanco, Lilly's animal health division in Greenfield, which has become increasingly important to Lilly as it braces for patent-protection losses.
More

Dow AgroSciences considered expansion elsewhere

March 5, 2010
Peter Schnitzler
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million expansion.
More

Dow Agro plans $340M expansion, 577 new jobs

March 4, 2010
Peter Schnitzler
The investment will greatly expand the company's research and development capacity and is a major win for the Indiana life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

Dow Agro plans 'major' expansion announcement

March 3, 2010
Peter Schnitzler
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
More

Lilly to shift more employees to Covance

February 26, 2010
J.K. Wall
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
More

Indiana companies that serve pharmaceutical industry grew in 2009

February 20, 2010
 IBJ Staff
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based life sciences trade group BioCrossroads.
More

Vortek Surgical moving HQ to Brownsburg, adding 60 jobs

February 18, 2010
 IBJ Staff
Indianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution operations and creating more than 60 jobs in the next three years.
More

Bioanalytical Systems reports quarterly loss

February 17, 2010
Bioanalytical Systems Inc., a West Lafayette-based life sciences contract research firm, on Wednesday reported a loss of $1.4 million for its fiscal first quarter.
More

Dow Agro CEO says pipeline of products strong

February 10, 2010
Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products by 2013 that could increase annual revenue by $800 million.
More

Report: State's pharmaceutical contractors continue to grow

February 10, 2010
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
More

Health care venture capital swoons in Indy, holds steady statewide

February 6, 2010
 IBJ Staff
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
More

Health firms still attracting venture capital

February 3, 2010
J.K. Wall
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis, but the rest of the state actually saw an increase.
More

Dow AgroSciences profit falls despite revenue increase

February 2, 2010
 IBJ Staff
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent from the prior year because of increased research and development spending and higher administrative expenses. Revenue was up 17 percent.
More

City of Greenwood might fund launch of insulin makerRestricted Content

January 30, 2010
Kathleen McLaughlin
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin, a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
More

TechPoint accepting nominations for Mira technology awards

January 23, 2010
 IBJ Staff
The awards are meant to showcase Indiana's high-tech success stories and raise the profile of the tech community.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am not by any means judging whether this is a good or bad project. It's pretty simple, the developers are not showing a hardship or need for this economic incentive. It is a vacant field, the easiest for development, and the developer already has the money to invest $26 million for construction. If they can afford that, they can afford to pay property taxes just like the rest of the residents do. As well, an average of $15/hour is an absolute joke in terms of economic development. Get in high paying jobs and maybe there's a different story. But that's the problem with this ask, it is speculative and users are just not known.

  2. Shouldn't this be a museum

  3. I don't have a problem with higher taxes, since it is obvious that our city is not adequately funded. And Ballard doesn't want to admit it, but he has increased taxes indirectly by 1) selling assets and spending the money, 2) letting now private entities increase user fees which were previously capped, 3) by spending reserves, and 4) by heavy dependence on TIFs. At the end, these are all indirect tax increases since someone will eventually have to pay for them. It's mathematics. You put property tax caps ("tax cut"), but you don't cut expenditures (justifiably so), so you increase taxes indirectly.

  4. Marijuana is the safest natural drug grown. Addiction is never physical. Marijuana health benefits are far more reaching then synthesized drugs. Abbott, Lilly, and the thousands of others create poisons and label them as medication. There is no current manufactured drug on the market that does not pose immediate and long term threat to the human anatomy. Certainly the potency of marijuana has increased by hybrids and growing techniques. However, Alcohol has been proven to destroy more families, relationships, cause more deaths and injuries in addition to the damage done to the body. Many confrontations such as domestic violence and other crimes can be attributed to alcohol. The criminal activities and injustices that surround marijuana exists because it is illegal in much of the world. If legalized throughout the world you would see a dramatic decrease in such activities and a savings to many countries for legal prosecutions, incarceration etc in regards to marijuana. It indeed can create wealth for the government by collecting taxes, creating jobs, etc.... I personally do not partake. I do hope it is legalized throughout the world.

  5. Build the resevoir. If built this will provide jobs and a reason to visit Anderson. The city needs to do something to differentiate itself from other cities in the area. Kudos to people with vision that are backing this project.

ADVERTISEMENT